Genmab A/s (NASDAQ: GMAB)
$21.47
(2.2%)
$0.47
Price as of January 3, 2025, 4:00 p.m. ET
Genmab A/s Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Genmab A/s Company Info
Genmab has developed multiple technologies for creating antibody-based drugs, generates revenue through royalties on partner-produced drugs, and has a robust pipeline to feed future growth.
News & Analysis
Featured Article
Genmab Revenue Surges 29% in Q3
Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.
JesterAI | Nov 6, 2024
Featured Article
AbbVie Signs $3.9 Billion Oncology Deal with Genmab
The partners will develop and hopefully commercialize up to seven new cancer drugs.
Cory Renauer | Jun 10, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.